C. Buddy Creech, Shannon C. Walker, Robert J. Samuels
Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit. Once this putative vaccine target was identified, the next challenge was how to best generate an effective immune response to SARS-CoV-2. The characteristics of this response would include production of neutralizing antibodies, generation of a T-cell response, and avoidance of immune-enhanced disease (vaccine-induced response that led to paradoxically increased disease severity on viral challenge).
Several vaccine designs were evaluated by different groups during the development of a SARS-CoV-2 vaccine…
JAMA April 6, 2021 Volume 325, Number 13
Published Online: February 26, 2021
© 2021 American Medical Association. All rights reserved.